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ProteolysisCalpain is an intracellular Ca2+-dependent cysteine protease (EC 3.4.22.17; Clan CA, family C02). Recent
expansion of sequence data across the species deﬁnitively shows that calpain has been present throughout
evolution; calpains are found in almost all eukaryotes and some bacteria, but not in archaebacteria. Fifteen
genes within the human genome encode a calpain-like protease domain. Interestingly, some human calpains,
particularly those with non-classical domain structures, are very similar to calpain homologs identiﬁed in
evolutionarily distant organisms. Three-dimensional structural analyses have helped to identify calpain's
unique mechanism of activation; the calpain protease domain comprises two core domains that fuse to form a
functional protease only when bound to Ca2+ via well-conserved amino acids. This ﬁnding highlights the
mechanistic characteristics shared by the numerous calpain homologs, despite the fact that they have
divergent domain structures. In other words, calpains function through the same mechanism but are
regulated independently. This article reviews the recent progress in calpain research, focusing on those
studies that have helped to elucidate its mechanism of action. This article is part of a Special Issue entitled:
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Of the many different proteolytic enzymes/systems, calpain (EC
3.4.22.17; Clan CA, family C02) is both unique and perplexing.
Nowadays, calpain homologs are deﬁned based on the primary
sequence characteristics of the calpain-like protease domain (CysPc)
(Fig. 1) [1–5]. This criterion has been used to identify various calpain
homologs in a wide range of living organisms (Fig. 2). Calpain, ﬁrst
identiﬁed in 1964 [6] and known by several different names ever since
[7–10], is an evolutionarily well-conserved protease family [11]. More
intriguingly, calpain superfamily members are sub-classiﬁed into
several groups according to their expression proﬁle or domain
structure. This is one of the topics covered in this review.
However, the physiological relevance of calpain (particularly with
respect to its positive effects) is difﬁcult to deﬁne. The involvement of
calpain activity in various pathophysiological phenomena has been
reported but usually as an aggravating factor [12–18]. Therefore,although it is accepted that the regulation of calpain is critical for cell
function, questions remain regarding when and how calpain is
activated. Genetic techniques (using both forward and reverse genetics)
have expanded our knowledge of the cause-effect relationships
between calpain deﬁciency and defective tissue function [19]. These
conditions, called “calpainopathies”, provide strong evidence for the
physiological importance of calpain. The ﬁndings of such phenotype-
oriented studies are also summarized in this review.
Another issue that has attracted attention is this: how does activated
calpain recognize its substrate? This is directly relevant to calpain-
mediated proteolysis, because calpain is different from other major
intracellularproteolytic components suchasproteasomes [20], autophagy
[21] and caspases [22] in one or both of two aspects. First, the action of
calpain on its substrate is known as “proteolytic processing” and the
product (the proteolyzed substrate) is different from its original
unproteolyzed form but is not degraded. In contrast, both proteasomes
and autophagy degrade the protein substrate. Second, calpain itself is
involved in substrate recognition, whereas proteasomes and autophagy
rely on their substrates being “tagged” by other systems, such as
ubiquitination and selective/non-selective autophagosome formation,
respectively. The caspase system recognizes substrates via short aa
sequences.
The mechanistic basis of calpain activation is becoming clearer
thanks to continuous efforts in resolving its 3-D structure. The 3-D
structures of the non-Ca2+-bound and Ca2+-bound forms of m-calpain
show that Ca2+-dependency is intrinsic to the CysPc domain [23–28]. In
addition, the existence of varied domain structures among calpain
homologs raises interesting questions, such as how the combination of
Fig. 1. Schematic structures of calpain superfamily members. A. Conventional calpains are composed of catalytic and small regulatory subunits. Domain structures are deﬁned
according to the text. Key structures for sub-classiﬁcation of calpain related molecules are indicated. N, N-terminal region; PC1/PC2, protease core domains 1/2; C2L, C2-like domain;
PEF(L/S), penta EF-hand domain in large(L)/small(S) subunit; GR, Gly-rich domain. *, avian CAPN11 is a catalytic subunit for a chicken conventional calpain designated as μ/m-
calpain, i.e., CAPN11/S1. B. Domain structure of the longest isoform of human calpastatin is shown. Four repetitive inhibitory units are labeled as domains 1 to 4; however, they do not
have any secondary structures. A-, B- and C-regions in each domain are important for inhibitory activity of calpastatin. The consensus aa sequence in B-region, which interact with
the active site of calpain, is shown. Exons encoding XL and L domains are subjected to alternative splicing.
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domain [4]. Therefore, the last part of this review focuses on the new
insights provided by detailed knowledge of calpain structure.
2. What is the calpain system?
2.1. Proposed uniﬁed nomenclature for calpains
The general concept underlying calpains was formulated from
studies on μ- and m-calpains [29] in mammals and μ/m-calpain in
birds [10,30]. These form the foundation of the calpain superfamily,
i.e., the conventional calpains. All other calpains are referred to as
“unconventional”. The structure of calpain is based on that of the
conventional calpains. There are, however, several points that prevent
the complete systematic classiﬁcation and citation of calpain-related
molecules. Recently, a thorough discussion among experts in the ﬁeld
led to the setting out of agreed principles of deﬁnition (Fig. 1A) [5].What was recommended is to adopt formal nomenclature system for
mammalian gene products such as CAPN1, CAPN2, and so forth to
distinguish gene products from enzyme entities (=“calpain”). Some
calpains previously known by independent names are denoted by
“the formal name [the old name]” system (e.g., CAPN3[p94] and
CAPN8[nCL-2]) in this review. Accordingly, conventional calpain
heterodimers are referred to as CAPN1[μCL] or CAPN2[mCL], and
CAPNS1[30K] (Table 1, Fig. 1A).
CAPN1[μCL] andCAPN2[mCL] are divided into fourdomains/regions:
the N-terminal anchor helix region, the CysPc protease domain, the C2
domain-like domain (C2L), and the penta-EF-hand domains (PEF(L))
[31]. CAPNS1[30K] contains an N-terminal Gly-rich (GR) domain and a
penta-EF-hand domain (PEF(S)). Themost important change is that the
protease domain (CysPc) now includes two core domains, PC1 and PC2,
which faithfully reﬂect the3-D structure of the non-Ca2+-bound formof
m-calpain (Fig. 1A, see Section 4.1) [23,24]. Names for calpain enzyme
entities such as μ-calpain and m-calpain are also proposed to be called
Fig. 2. Structural classiﬁcation of calpain. A. Calpain homologs have been identiﬁed in almost all eukaryotes and in some bacteria. Based on the structural essence, non-classical
calpains are further sub-classiﬁed. Their distribution in various organisms is also summarized. MIT, microtubule-interacting and trafﬁcking domain, C2, C2-domain; Zn, Zn2+-ﬁnger-
containing domain; SOH, SOL-homology domain; TM, transmembrane domain. For other symbols, please refer to Fig. 1A legend. a, in eutherian CAPN6 homologs, the active site
cysteine are substituted to other amino acids. b, the number of Zn2+-ﬁnger motifs varies according to the organisms: 0 in some of fungi and nematode homologs, 6 in ﬂy, and 5 in
humans. c, the TM domain is missing in nematode and ﬂy homologs. B. Phylogenetic tree of human calpains. The tree was drawn by the neighbor-joining/bootstrap method using
MAFFT v6.240 (http://align.genome.jp/mafft/, strategy: E-INS-i). Each calpain homolog is represented by number, i.e., 1, CAPN1; 2, CAPN2; etc. It is noted that classical calpains and
non-classical calpains form into two distinct islands, and that non-classical calpains tend to diverge from each other as detected by the length from branching points.
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for μ-calpain and CAPN2/S1 for m-calpain.
2.2. Overview of calpain homologs
Calpains belong to the papain superfamily of cysteine proteases. To
be considered a calpain homolog, it is critical that a protein has aa
sequences that are signiﬁcantly similar to those of the CysPc domainsof CAPN1[μCL] and CAPN2[mCL]. According to this criterion, the
human genome contains 15 genes that encode calpains (Table 1). A
recent survey of the sequence database revealed that calpain genes
are present in a wide range of living organisms, including prokaryotes
(Fig. 2A) [4]. Interestingly, calpain genes are not so common in lower,
primitive organisms. For example, to date, no calpains have been
identiﬁed in 95% of the known bacterial genomes, including
Escherichia coli and all archeabacteria. On the other hand, calpain
Table 1
Human genes for calpain and calpain-related molecules.
Gene Chromosome Product name[also known as] Tissue-speciﬁcity Structurea Representative homolog Splice variantb
CAPN1 11q13 CAPN1[μCL] Ubiquitous Classical
CAPN2 1q41-q42 CAPN2[mCL] None in erythrocytes Classical
CAPN3 15q15.1-q21.1 CAPN3[p94] Skeletal muscle Classical +
CAPN5 11q14 CAPN5[hTRA-3] Ubiquitous Non-classical TRA-3 in nematode
CAPN6 Xq23 CAPN6[CANPX] Embryonic muscles, placenta Non-classical TRA-3 in nematode
CAPN7 3p24 CAPN7[PalBH] Ubiquitous Non-classical PalB in Aspergillus,
Rim13/Cpl1 in yeast
+
CAPN8 1q41 CAPN8[nCL-2] Gastrointestinal tracts Classical +
CAPN9 1q42.11-q42.3 CAPN9[nCL-4] Gastrointestinal tracts Classical +
CAPN10 2q37.3 CAPN10 Ubiquitous Non-classical +
CAPN11 6p12 CAPN11c Testis Classical
CAPN12 19q13.2 CAPN12 Hair follicle Classical +
CAPN13 2p22-p21 CAPN13 Ubiquitous Classical
CAPN14 2p23.1-p21 CAPN14 Ubiquitous Classical
CAPN15 (SOLH) 16p13.3 CAPN15[SOLH] Ubiquitous Non-classical SOL in Drosophila
CAPN16 (C6orf103) 6q24.3 CAPN16[demi-calpain, C6orf103] Ubiquitous Non-classical
CAPNS1 19q13.1 CAPNS1[30K] Ubiquitous N/A
CAPNS2 16q12.2 CAPNS2 Ubiquitous N/A
CAST 5q15 Calpastatin Ubiquitous N/A +
a Classical or non-classical indicates that the molecule has or does not have tandem structure of CysPc-C2L-PEF(L), and N/A means not applicable.
b + indicates that alternatively spliced variants are generated from the same gene.
c Avian CAPN11 is also called μ/mCL.
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irregular cases such that Saccharomyces cerevisiae has a calpain gene,
RIM13/CPL1, while certain other unicellular organisms such as
Encephalitozoon and Schizosaccharomycete do not. Nevertheless,
divergent bacterial and yeast calpain sequences suggest that the
calpain superfamily represent the oldest branch of the papain
superfamily although the origin of calpains during evolution is
difﬁcult to determine [11]. From this aspect, comparative analysis of
the sequences of calpain homologs from various organisms represents
one of dynamic approaches to comprehend this unique protease
family [4].
Generally, the calpain homologs are further classiﬁed according to
two different criteria [4,5,32], which will be summarized in the
following Sections, 2.3 and 2.4.
2.3. Structure-oriented classiﬁcation of calpain superfamily members
The domain structure of the catalytic subunits of the mammalian
conventional calpains, CAPN1[μCL] or CAPN2[mCL], is deﬁned as
“classical”. The classical structure comprises the C2L and PEF domains
plus the CysPc domain (Fig. 1A). Accordingly, “non-classical” calpains
(some of which are products of alternative splicing from classical
calpain genes) exclude C2L and/or PEF domains [33]. Additional
domain structures are found within both classical and non-classical
calpains. These structures have provided hints with respect to the
cellular mechanisms and/or conditions under which speciﬁc calpain
homologs operate [34–36].
2.3.1. Classical calpains
In humans, nine out of 15 calpain genes encode the classical calpains,
CAPN1[μCL], CAPN2[mCL], CAPN3[p94], CAPN8[nCL-2], CAPN9[nCL-4],
and CAPN11 to CAPN14 [37]. Most of classical calpains are conserved in
vertebrates, among which ﬁsh have a duplicate set of these genes [38].
Few invertebrates have genes encoding classical calpains; the blood
ﬂuke Schistosoma mansoni has four [39], and the fruit ﬂy Drosophila
melanogaster and the Africanmalariamosquito Anopheles Gambiae each
have three [40]. No classical calpain homologs have been found in
nematodes [41], trypanosomes [42], plants [43,44], fungi, or yeast [45].
Comparison of the known properties of human classical calpains
clearly shows that sequence similarities do not necessarily reﬂect
functional and/or biochemical similarities. For example, of the human
classical calpains, only CAPN1[μCL] and CAPN2[mCL] form hetero-dimers with CAPNS1[30K] in vivo. The question is, therefore: what is
the prototype calpain? In otherwords, although studies ﬁrst identiﬁed
conventional calpains, they may be quite new in evolutionary terms.
Another interesting point is that orthologous calpain species do not
necessarily have similar function. This is exempliﬁed by CAPN11. Avian
CAPN11 forms heterodimers with CAPNS1[30K] to form the conven-
tional μ/m-calpain (CAPN11/S1), which is expressed ubiquitously,
whereas expression of avian CAPN1 and CAPN2 is markedly low and/
or restricted to speciﬁc tissues. By contrast, in eutherians (such as
humans), CAPN11 is speciﬁc to the testis and there is no evidence to
suggest its involvement in the formation of CAPN11/S1[μ/m-calpain]
[46]. Furthermore, the CAPN11 gene is not present in marsupialia [37].
Another example is theCAPN8[nCL-2] ortholog, xCL-2, inXenopus laevis.
Phenotypes caused by the disruption of the Capn8 gene in mice are
speciﬁc to gastrointestinal tract [47], but severe developmental defects
occur in frogs [48].2.3.2. Non-classical calpains
Non-classical calpains are further divided into several subfamilies
according to structural characteristics (Fig. 2A). In each subfamily,
again, structural similarity does not necessarily implicate similar
functions. The following subgroups categorize most of eukaryotic
non-classical calpains known so far: PalB, SOL, and DEK1 subfamilies
(Fig. 2A).
The PalB subfamily is themost evolutionarily conserved. It is found
in humans, fungi, yeast, protists, nematodes, and insects except fruit
ﬂy, but not in plants [49]. PalB is a calpain homolog ﬁrst identiﬁed in
Emericella nidulans as the product of the gene responsible for the
fungi's adaptive responses to alkaline conditions [50–52]. Studies of
PalB homologs in fungi exempliﬁed the power of cutting edge genetic
approaches to examine the physiological functions of calpain, which
will be described later in this review [53,54]. The general consensus
regarding the PalB-type structure is that it contains two tandem C2L/
C2 domains at the C-terminus of the CysPc domain. PalB homologs are
further divided into three groups by structure (Fig. 2A). In the PalB
group and the CAPN10 group, two tandem C2L domains exist and each
C2L domain has varying extent of divergence from those in classical
calpains. Another variation is the TRA-3 group, which contains one
C2L domain and one C2 domain in tandem. TRA-3[CLP-5] was
originally identiﬁed in nematodes and, later, its vertebrate homolog,
CAPN5[hTRA-3], was identiﬁed [55,56].
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in almost all animal species, including humans, insects, nematodes,
and green algae. In vertebrates, SOL homologs correspond to CAPN15.
SOL homologs are characterized by a speciﬁc SOL-homology (SOH)
domain at the C-terminus of CysPc, and several Zn2+-ﬁnger motifs
within the N-terminal domain. For example, Drosophila SOL, the
product of the gene causing the small optic lobes (sol) when mutated
[57], contains six Zn2+-ﬁnger motifs, while human SOL (CAPN15)
contains ﬁve [58,59]. Thus far, there is no direct evidence implicating
Zn2+ in the regulation of SOLH; however, it is anticipated that further
study of this evolutionarily interesting group will uncover the
regulatory mechanisms of CysPc function.
Plant calpains, knownasphytocalpains, compriseanother interesting
branch of the non-classical calpains, the DEK1 subfamily [60–62]. The
representative maize DEK1 (defective kernel 1) molecule is involved in
aleurone cell development [43]. DEK1 homologs are also found in other
plants, including rice plants [63] and Arabidopsis [64–66]. These DEK1
homologs commonly contain one C2L domain at the C-terminus and a
trans-membrane (TM) domain at theN-terminus. The structure of DEK1
homologs within the animal kingdom, however, is more diverse. For
example, Tetrahymena thermophile expresses a calpain that has over all
similarity toplantDEK1,whereasnematodehomologs (CLP-3, -4, -6, and
-7) do not contain a TM domain. Although topology of the N-terminal
region needs to be determined, the CysPc domain was shown to be
located in the cytosol and detached from the cell membrane via
intramolecular autolytic cleavage [67]. A study using a recombinant
DEK1 CysPc domain suggested that DEK1 is, in fact, a Ca2+-dependent
cysteine protease [60]. Taken together, these features suggest that the
DEK1 may provide a promising line of research into the divergent, but
basically conserved, functions of a calpain superfamily.
Because calpain homologs in prokaryotes are rather divergent
from one another as well as human calpains, and lack a shared domain
structure (apart from the CysPc domain), these calpain homologs are
collectively referred to as “bacterial calpain” [4]. There is also an
uncharacterized, yet potentially interesting gene product in humans,
tentatively named CAPN16 or demi-calpain, due to the fact that it
contains only the N-terminal half of CysPc (PC1).
2.4. Classiﬁcation of calpain family according to expression proﬁle
Of the 15mammalian calpain genes, six are considered to be tissue-
speciﬁc according to the expression of theirmajor protein products. The
other calpains, including the conventional calpain catalytic subunits,
CAPN1[μCL] and CAPN2[mCL], are ubiquitously expressed. It is widely
assumed that ubiquitous calpains play a fundamental role in all cells,
whereas tissue-speciﬁc calpains are involved in more speciﬁed cellular
functions. In fact, defects in ubiquitous calpainsmay be lethal, as seen in
Capn2−/− mice [68], whereas defects in tissue-speciﬁc calpains may
cause tissue-speciﬁc phenotypes such asmuscular dystrophy caused by
mutations in CAPN3 [69].
In general, under disease/damaged conditions, such as muscular
dystrophy, cardiomyopathy, traumatic ischemia, or lissencephaly, the
over-activation of conventional calpains (probably due to compromised
intracellular Ca2+ homeostasis) has been identiﬁed as an exacerbating
factor [70]. Thus, the physiological activity of conventional calpains
tends to be analyzed with respect to speciﬁc inhibition, resulting in the
attenuation of pathological symptoms [71]. In contrast, the study of
tissue-speciﬁc calpains is based upon the assumption that they are
purposely expressed within a tissue and are, therefore, involved in the
speciﬁc functions of that tissue.
The tissue-speciﬁc calpains that have been identiﬁed to date are:
CAPN3[p94] in skeletal muscle [72], CAPN6 in placenta and embryonic
striated muscle [73,74], CAPN8[nCL-2] and CAPN9[nCL-4] in the
gastrointestinal tract [33], CAPN11 in the testis [46,73], and CAPN12 in
hair follicles [75]. As to the structures of the gene promoter regions,
which are most likely responsible for the speciﬁc expression proﬁlesof each homolog, not much has been clariﬁed. In the case of CAPN3,
highly conserved structures containing a TATA-box and several E-
boxes have been identiﬁed in the immediate upstream regions of
human, mouse and rat CAPN3/Capn3 [76], while several other
promoter regions that show distinct expression proﬁles were also
identiﬁed [77]. The promoter region of Capn8 contains several GATA
boxes, two TATA boxes and some cAMP responsive elements [78].
Interestingly, the human and murine CAPN8/Capn8 gene is located in
close proximity to CAPN2/Capn2 on chromosome 1, and their
transcripts have overlapping complementary sequences.
2.5. Regulatory components of the calpain system
Besides various calpain homologs, there are twomolecules that are
essential regulatory components of the calpain system: CAPNS1[30K]
and calpastatin. Since the impact of these molecules, either positive or
negative, is limited to a few calpains, the question remains as to when
these proteins were incorporated into the calpain system during
evolution.
2.5.1. Small regulatory subunit of conventional calpains
Like classical calpains, CAPNS1[30K] also contains ﬁve EF-hand
motifs, referred to as PEF(S) (Fig. 1A). In mammals, the interaction
between the ﬁfth EF-hand motif of CAPNS1[30K] and CAPN1[μCL] or
CAPN2[mCL] generates heterodimeric conventional calpains [23,24],
as expected from the previous biochemical study [79] and the 3-D
structure of the CAPNS1[30K] homodimer [80,81]. The N-terminus of
CAPNS1[30K] contains hydrophobic Gly-clusters, most of which are
autolyzed during the activation of conventional calpains. No particular
conformation was identiﬁed in this region by 3-D structural analysis
and it is tentatively referred to as the Gly-rich (GR) domain.
Biochemical study suggested that CAPNS1[30K] functions as a
chaperone-like component for nascent catalytic subunits of the
conventional calpains [82]. Accordingly, Capns1−/−mice are embryonic
lethal, barely surviving beyond E11.5, because both CAPN1[μCL] and
CAPN2[mCL] proteins are down-regulated, indicating that CAPNS1[30K]
is an absolute requirement for the stability of both conventional calpain
catalytic subunits in vivo [83,84]. So far, such drastic importance of
CAPNS1[30K] has only been observed for CAPN1[μCL] and CAPN2[mCL].
In the human genome, ﬁve other genes encode proteins containing
a PEF domain besides the classical calpains and CAPNS1[30K] [85].
One of these proteins, CAPNS2[30K-2], is signiﬁcantly similar to
CAPNS1[30K] [86]. At present, the physiological role of this protein is
unclear.
2.5.2. Calpastatin — a speciﬁc and unique calpain inhibitor
Calpastatin is the only known endogenous speciﬁc inhibitor for
conventional calpains [87]. Of the calpain homologs so far examined,
CAPN8[nCL-2] [88] and CAPN9[nCL-4] [89], but not CAPN3[p94] [90],
are also inhibited by calpastatin in vitro. Although calpastatin is
effectively proteolyzed by CAPN3[p94], the physiological signiﬁcance
of this propensity is not clear.
One calpastatin molecule contains four inhibitor units, each unit
inhibiting one calpain molecule with variable efﬁciency [91–93]
(Fig. 1B). Peptide sequences as short as 20 aa derived from these
inhibitory units are capable of inhibiting calpain, although at the low
efﬁcacy. The sequence of calpastatin is poorly conserved between
species and, therefore, the speciﬁcity of its effect on calpain is difﬁcult
to explain. Recently, the 3-D structure of CAPN2/S1[m-calpain] (co-
crystallized with one of the inhibitory units of calpastatin and Ca2+)
partly revealed the trick; the structural “softness” of calpastatin,
which has been cited as “intrinsically unstructured”, enables tight
binding to calpain while, at the same time, allowing the adjacent
several aa residues to loop out from the active site of calpain, thereby
keeps itself from proteolysis [27,28] (Fig. 1B).
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The importance of proteolytic systems for maintaining cellular
function has been increasingly recognized. Calpains, one of the major
intracellular proteolytic enzymes, are no exception. The impact of
calpain function depends on the nature of the particular protein
substrate and the particular conditions investigated [94–100]. In this
section, three examples (fungus PalB, mammalian CAPN3[p94], and
mammalian CAPN8[nCL-2]/CAPN9[nCL-4]) are discussed (Fig. 3).
3.1. PalB as a key molecule in an environmental adaptation of fungi
E. nidulans is a microorganism that grows over a wide pH range.
Therefore, adaptive mechanisms to environmental changes are critical
for the life of this unicellular eukaryote. The pal (phosphatase mutants:
loss in activity at alkaline pH but normal or increased activity at acidicFig. 3. Examples of calpain's function in vivo. A. PalB is involved in the proteolytic activa
environment. PalB is translocated to ESCRT-III complex via the interaction through its N-term
CAPN3[p94] is a product of the gene responsible for LGMD2A. The lack of protease activity o
amount of loads is imposed on the tissue. It is anticipated that characteristics of CAPN3, such
response of skeletal muscle. C. CAPN8[nCL-2] and CAPN9[nCL-4] form a protease complex des
as an exposure to high dose of ethanol, multiple signaling cascades are induced. One of thes
protection of mucosal tissue.pH)mutants showgene expression proﬁles suited to acid environments,
even under normal/neutral conditions; thus, they are unable to grow
under alkaline conditions [50]. PalB, together with other pal gene
products, is involved in theproteolytic activationof PacC (Fig. 3A). PacC is
a key transcription factor that regulates pH-dependent changes in gene
expression. The full-length PacC protein has an inactive conformation
and is activated by a two-step proteolytic conversion process [101,102].
The ﬁrst step is pH-dependent and is catalyzed by PalB, while the second
is thought to be mediated by the proteasome in a pH-independent,
constitutive manner. This pH adaptation system is called the Pal-PacC
pathway, in which PalB functions as an important rate-limiting factor,
e.g., a modulator protease.
The physiological importance of the Pal–PacC pathway is
suggested by the fact that it is well conserved in yeasts, and some
components in the pathway have mammalian homologs that are
involved in signaling cascades. The PalB orthologs are Rim13[Cpl1] intion of PacC, a key transcription factor for the survival of E. nidulans under alkaline
inal tandem domains so that it is activated to process PacC. B. Skeletal muscle-speciﬁc
f CAPN3 causes defective homeostatic response of skeletal muscle when the excessive
as Na+-dependent activation is critical for its function as a component of homeostatic
ignated as CAPN8/9[G-calpain] (G, gastric). When gastric tissue experiences stress, such
e cascades is dependent on CAPN8/9[G-calpain] protease activity and necessary for the
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(Regulators of Ime2) proteins compose a pH adaptive system as well
as those for meiosis and sporulation, in which the proteolytic
processing of Rim101, a counterpart of PacC, by Rim13[Cpl1] is the
critical step [54,103,104]. Unlike PacC, the involvement of proteasome
in the activation of Rim101 has not been reported. As mentioned,
Schizosaccharomycetes have no PalB ortholog, suggesting that molec-
ular components for the signaling pathway regulating tolerance to
particular environmental changes have been modiﬁed throughout
evolution.
Another remarkable feature of these signaling pathways is that
they involve membrane trafﬁcking components known as ESCRT
(endosomal sorting complex required for transport) and Vps
(vacuolar protein sorting) proteins [105,106]. Genetic analyses have
identiﬁed the functional and hierarchical relationships between the
Rim and Vps proteins, along with the relevance of the ESCRT-III sub-
complex as a scaffold for Rim13[Cpl1] function [54,107,108]. Some of
the physical interactions between ESCRT and Vps proteins are
conserved in yeast and mammals [109–112]. The interaction between
CAPN7[PalBH] and CHMPs (charged multivesicular body protein) is
another example of these conserved interactions. Thus, it is expected
that systemic analogy exists between fungi and eukaryotes, even
though the situations that necessitate the activation of these systems
differ. Further study of this phenomenon would greatly contribute to
our knowledge of the physiological functions of CAPN7[PalBH] in
mammals.
3.2. CAPN3[p94] and homeostasis in skeletal muscle
The ﬁrst tissue-speciﬁc calpain, CAPN3[p94], was identiﬁed in
1989 [72]. CAPN3[p94] is expressed predominantly in skeletal muscle.
Structurally, it is categorized as a classical calpain and is approxi-
mately 50% identical to CAPN1[μCL] and CAPN2[mCL]. The important
characteristic of CAPN3[p94], however, is that it contains three
additional insertion regions (known as NS, IS1, and IS2), located,
respectively, at the N-terminus, within PC2 of CysPc, and between the
C2L and PEF(L) domains. These regions give CAPN3[p94] some unique
features.
In 1995, a study involving positional cloning analysis of families
from La Reunion Island reported that CAPN3 mutations were
responsible for limb-girdle muscular dystrophy type 2A (LGMD2A),
also called calpainopathy, [69]. Capn3−/− mice show a human
calpainopathy-like phenotype, although milder, indicating that
calpainopathy is indeed caused by CAPN3 defects [113,114].
LGMD2A and CAPN3 mutations are the only examples of a clear
cause–effect relationship between human disease and calpain gene
mutations identiﬁed so far.
Attempts to identify the speciﬁc CAPN3[p94] defects that cause
LGMD2A were undertaken using CAPN3[p94] knock-in (Capn3CS/CS)
mice, which express a structurally intact but protease-inactive CAPN3
[p94]:C129S mutant [36,115]. These studies suggested that A)
“calpainopathy” is primarily caused by compromised CAPN3[p94]
protease activity; B) Capn3CS/CS mice show a less severe phenotype
than Capn3−/−mice; and C) Capn3−/−mice, but not Capn3CS/CS mice,
show reduced Ca2+ release from the sarcoplasmic reticulum.
Therefore, at least two activities of CAPN3[p94] (proteolytic and
non-proteolytic) are involved in its physiological function.
Skeletal muscle comprises the largest tissue mass in the human
body and is both a device for motility and a source of metabolic
activity and nutrition. Multiple mechanisms protect skeletal muscle
from damage and stress, which are almost inevitable in daily life.
Obviously, removal of damaged proteins from sarcomere is one
important strategy for keeping the quality of myoﬁbrils. There have
been discussions about what kind of proteolytic system(s) is (are)
suitable for such missions [116,117]. Some of unique properties of
CAPN3, such as apparently Ca2+-independent activation [118,119]and interaction with connectin/titin, a gigantic sarcomere protein
[120,121], together with the phenotypes of Capn3−/−mice [113,114],
highlight the possibility that CAPN3 is involved in a homeostatic
mechanism of skeletal muscle [114,122] (Fig. 3B). As to how CAPN3
protects skeletal muscle from damaging stimuli, other scenarios are
also possible. Analysis of exercise-induced muscle degeneration
suggests that another homeostatic mechanism in Capn3CS/CS skeletal
muscle, namely the adaptive upregulation of muscle ankyrin-repeat
protein-2 and heat shock proteins, is compromised [115]. Together, it
is suggested that mutations in CAPN3 disrupt its activity to control
multiple aspects of the homeostatic mechanisms within skeletal
muscle, resulting in LGMD2A.
The targets of CAPN3[p94] protease activity are of major interest in
the ﬁeld of calpain research. Along with straightforward approach to
identify its substrate proteins, the behavior of CAPN3[p94] under
various conditions is indicative of its function. In this respect, the
correlation between the distribution kinetics of CAPN3[p94] within
the sarcomeres and its protease activity may warrant further
investigation, as this phenomenon indicates that the protease activity
of CAPN3[p94] affects its sensitivity and/or reactivity to conditions
within the sarcomere [36,123].
3.3. CAPN8[nCL-2] and CAPN9[nCL-4] complexes as a defense against
gastric stimulation
Both CAPN8[nCL-2] and CAPN9[nCL-4] are predominantly
expressed in the surface mucus cells (pit cells) of the stomach
[124]. Smaller amounts are expressed in goblet cells in the intestines.
Based on primary sequence data, both of these calpain homologs are
classical calpains but they are located at slightly different positions
with respect to the other calpains. Of the mammalian calpains, CAPN8
[nCL-2] is the most similar to CAPN2[mCL] (62% identical), while
CAPN9[nCL-4] is equally similar to all other classical calpains.
Therefore, these two calpains appear not to be the closest relatives
from an evolutionary perspective.
Previous studies of CAPN8[nCL-2] and CAPN9[nCL-4] placed an
emphasis on characterizing their similarities and/or differences. These
approaches revealed that both calpain homologs are Ca2+-dependent
and sensitive to known calpain inhibitors, and that CAPN9[nCL-4], but
not CAPN8[nCL-2], requires CAPNS1[30K] for its activity in vitro [88].
However, a recent study using Capn8−/− and Capn9−/− mice
showed that neither CAPN8[nCL-2] nor CAPN9[nCL-4] forms a stable
complex with CAPNS1[30K] in vivo [47]. Rather surprisingly, they
form a hybrid complex in vivo, termed as gastric calpain (G-calpain,
CAPN8/9). The disruption of either Capn8 or Capn9 causes the down-
regulation of the other molecule, suggesting that each species
contributes to the stability of the other. Although trace amounts of
CAPN8[nCL-2] or CAPN9[nCL-4] can be detected in the absence of the
other, they are not proteolytically active.
Both Capn8−/− and Capn9−/− mice, which are essentially double
knockout mice, show no symptoms under normal conditions but are
signiﬁcantly more susceptible to ethanol-induced gastric ulcers. This
phenotype is unchanged in CAPN8[nCL-2] knock-in (Capn8CS/CS) mice,
which express a mutant CAPN8/9[G-calpain] complex that only
retains the protease activity of CAPN9[nCL-4]. Therefore, CAPN8/9
[G-calpain], with dual protease activity, is an essential component of
stomach tissue that resists gastric stimulation. This is a novel and
unique form of active calpain complex. Considering that pit cells
speciﬁcally function as a disposable barrier, it is assumed that the
CAPN8/9[G-calpain] complex plays a role in the sensitivity and/or
reactivity of pit cells to imposed stress [47] (Fig. 3C).
Taking advantage of recent improvements in a single nucleotide
polymorphism (SNP) database, human CAPN8 and CAPN9were found
to contain several aa-substituting SNPs. An in vitro expression study
showed that the introduction of some of these SNPs compromised the
proteolytic activity of CAPN8/9[G-calpain] complex. Apparently, none
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individuals with particular SNPs develop pathological symptoms such
as gastric ulcers and gastritis. It should be mentioned that, in terms of
a general health issue, this approach is the ﬁrst example showing that
the investigation of calpain function in transgenic animals can be
extended to human disease.
4. How does calpain work?
4.1. Insights into the structural identity of CysPc
The ﬁrst evidence of calpain structure–function relationships was
provided by the primary sequence of chicken CAPN11 [30]. This
structure has both a cysteine protease domain and a Ca2+-binding PEF
domain, consistent with the preceding biochemical studies on its Ca2+-
dependent protease activity. Later, when the Ca2+-free 3-D structure of
CAPN2/S1[m-calpain], i.e., a heterodimer of CAPN2[mCL] and CAPNS1
[30K],was solved, itwas found that the protease domain is split into two
halves, and that the active-site residues and potential substrate binding
cleft have non-functional conformations [23,24]. Therefore, the calpain
protease (CysPc) domain was characterized as two core domain
structures, PC1 and PC2 [5], within one protease domain.
Subsequently, structural studies of calpain were directed at
deciphering the mechanism underlying Ca2+-binding, which trans-
forms calpain into its active conformation. One of the difﬁculties in
deducing the mechanisms involved in calpain activation by Ca2+ was
that it did not appear theoretically feasible that Ca2+-binding to the
PEF domains would cause conformational changes sufﬁcient to fuse
the two core domains into a functional protease domain unless novel
Ca2+ binding sites were assumed. In fact, the CysPc domain itself has
Ca2+-dependent protease activity, although its speciﬁc activity is very
low [125,126].
So far, 3-D structures of CysPc domains from CAPN1[μCL], CAPN2
[mCL], CAPN8[nCL-2], and CAPN9[nCL-4] in the presence and/or
absence of Ca2+ have been solved, revealing the following: A) These
structures are highly similar to one another with a few differences
[25,26,127] (Table 2 and Fig. 4A). B) Two Ca2+-binding sites (CBS-1
and -2 in PC1 and PC2, respectively) are present within the CysPc
domain [25]. C) In the presence of Ca2+, PC1 and PC2 move closer to
each other although the secondary structures are essentially
unchanged (except CAPN9[nCL-4]). PC2s of active CAPN1[μCL],
CAPN2[mCL], and CAPN8[nCL-2] are rotated and translated by ca.
50° and 6 Å, respectively, when the alignment of PC1s of them and
inactive CAPN2[mCL] is ﬁxed [128] (Fig. 4A). D) The structure of the
CBS-1 and -2 is unique and there is, so far, only one example showing
similarity to CBS-1 (known as the “Ca2+-bowl”) although there is no
sequence similarity between them. Ca2+-bowl is found in the high-
conductance voltage- and Ca2+-activated K+ (BK or SLO1) channelTable 2
Similarities of 3D structures of mammalian calpain protease domains. Pairwise alignment
(http://ekhidna.biocenter.helsinki.ﬁ/dali_lite/) [151]. Upper right and lower left values indi
similar; Z=2, 5, and 8 correspond to P=0.023, 2.9×10−7, and b10−15, respectively) and R
to when CysPc, PC1, or PC2 domains are compared with each other, respectively). All stru
except CAPN9 are aligned with RMSD not more than 1.2 Å, and each of PC1 and PC2 of
(RMSDN6 Å) (see also Fig. 4A). Species: 1MDW, rat; all others, human.
aDali failed to compare whole CysPc domains of 1KFU and 1ZIV due to too divergent struct[129]. E) The active-site cleft of the calpain CysPc domain is rather
deep and is narrower than that in papain-like cysteine proteases
[130]. Therefore, it is thought that the substrate must be in an
extended conformation to ﬁt the cleft which, in turn, explains
calpain's preference for digesting inter-domain unstructured regions.
The 3-D structure of the complete CAPN2/S1[m-calpain] molecule
co-crystallizationwith calpastatin and Ca2+ ﬁnally conﬁrmed that Ca2
+-binding to CBS-1 and CBS-2 causes dynamic changes in the relative
conformation of PC1 and PC2 [27,28]. Consistent with previous
observations made using alternative approaches such as CD spectral
analysis and small-angle X-ray scattering analysis, Ca2+-binding to
calpain does not change its secondary structure but rather rearranges
the domains [131,132]. For example, Ca2+-binding to the PEF domains
barely changes the secondary structure but induces displacement of
the N-terminal region from the protease core region.
Are the characteristics of the different calpain species explained
based on their structure, i.e., .by the comparison of the 3-D structure of
their CysPc domains? The answer is “yes” and “no”. For example, in the
protease domain of CAPN2[mCL] and CAPN8[nCL-2], a Trp residue is
projected like a barrier to the active site [26]. This is referred to as a
reversible intrinsic inhibitory mechanism and was thought to discrim-
inate CAPN2[mCL] from CAPN1[μCL]. However, the complete 3D
structure of CAPN2/S1[m-calpain] does not infer such a mechanism.
Therefore, analyzing the domain structures in isolation gives a
convenient snapshot but does not necessarily reﬂect the full nature of
the complete molecule, at least in a resting state. In other words, inter-
domain, or even inter-molecular, interactions should be taken into
account as factors modifying the essentially conserved nature of the
CysPc domains. This notion could be extended to deal with the
activation and latency mechanisms in vivo that must be specialized for
each molecule [127].4.2. Variable parameters involved in calpain activation
Of the mammalian calpains, CAPN1[μCL] and CAPN2[mCL] hetero-
dimerize with CAPNS1[30K] to form functional proteases and the
activation mechanisms involved have been identiﬁed (see above).
However, the functional entities within the other calpain species
remain unknown. For example, the mechanism how CAPN8[nCL-2]
and CAPN9[nCL-4] cooperate with each other to function as CAPN8/9
[G-calpain] requires further investigation. It is expected that other,
less characterized calpains' activation may be subject to redeﬁnition
as research progresses. As one of clues to the activation mechanism,
unique structures identiﬁed in certain calpain species have proved
useful. Knowledge about such species-speciﬁc activation mechanisms
would promote the investigation of physiological functions, and vice
versa.of each pair of CysPc domains of calpains indicated was performed using Dali server
cate Z-scores (the number of standard deviations; the larger Z value means the more
MSD (root-mean-square deviation, Å), respectively (three values, X (Y/Z), correspond
ctures except 1KFU are Ca2+-bound active structures. Note that all active structures
CAPN9 is also well aligned (RMSD≤1.7 Å) although whole CysPc of CAPN9 is not
ures.
Fig. 4. Comparison of the 3-D structures of the CysPc and C2L domains of mammalian calpains. A. The CysPc domains of active Ca2+-bound CAPN1[μCL] (PDB accession No: 2ARY,
blue), CAPN2[mCL] (1MDW, red), CAPN8[nCL-2] (2NQA, white), and CAPN9[nCL-4] (1ZIV, green), and inactive non-Ca2+-bound CAPN2[mCL] (1KFU, black) are aligned in their PC1
domains using MolFeat Ver.4.6 (FiatLux Inc.), and represented as a cross-eye stereo ribbon scheme. Cys, Trp, His, and Asn indicate C115/105/105/97 (for CAPN1[μCL], CAPN2[mCL],
CAPN8[nCL-2], and CAPN9[nCL-4], respectively), W116/106/106/98, H272/262/262/254, and N296/286/286/278, respectively, which are active site triad residues and the Trp
residue “interfering” them in CAPN2[mCL] and CAPN8[nCL-2]. Whereas active CAPN1[μCL], CAPN2[mCL], and CAPN8[nCL-2] are almost completely aligned, inactive CAPN2[mCL] is
moderately aligned, and active CAPN9[nCL-4] is misaligned (see also Table 2). B. Schematic cross-eye stereo ribbon structures of the C2L domains of the active (3BOW, red, a part of
co-crystalized calpastatin structure is also shown as ball-stick scheme) and inactive (1KFU, white) forms of CAPN2[mCL] and the distal part of CAPN7[PalBH] (2QFE, blue),
superimposed using Dali pairwise comparison (http://ekhidna.biocenter.helsinki.ﬁ/dali_lite/). Both molecules showed fairly good superimposition (RMSD=2.0 Å), but several
loops showed signiﬁcant differences.
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autolytic activity serves as one indicator of activity. For example,
CAPN7[PalBH] expressed in cultured cells as an EGFP-fusion protein
shows autolytic activity [35]. Using this fusion construct, it was shown
that IST1, a protein that interacts with CAPN7[PalBH], enhances its
autolytic activity. This interaction is mediated by the MIT domains
within CAPN7[PalBH] and the MIM domains in IST1. This type of
interaction is analogous to that observed in proteins involved in the
ESCRT system in yeast. IST1 is, in fact, related to ESCRT-III complex
proteins. Thus, it is suggested that the MIT domains within CAPN7
[PalBH] form a complex with IST1 to enhance the conversion of CysPc
to its active conformation. In E. nidulans and S. cerevisiae, activation of
PalB involves its translocation to the ESCRT-III complex [54,106]. In
this respect, the effect of IST1 on the localization and activation ofCAPN7[PalBH] is worthy of further investigation, although the
physiological target for activated CAPN7[PalBH] remains unknown.
Another example of a unique modiﬁcation within CysPc is CAPN3
[p94]. CAPN3[p94] autodegrades very quickly, an activity that depends
on the speciﬁc insertion sequences, IS1 and IS2, locatedwithin PC2 and
the junction between the C2L and PEF domains, respectively [118].
Recently, it was shown that this autodegradation is Na+-dependent in
the absence of Ca2+, establishing CAPN3[p94] as the ﬁrst example of
an intracellular Na+-dependent enzyme [119]. Mutation analyses
suggest that IS1 and IS2 are required for this Na+-dependency, and
that acidic amino acids located within CBS-1 mediate Na+-binding to
the CysPc of CAPN3[p94]. Some alternative splice variants produced
from CAPN3/Capn3 lack IS1 and/or IS2, and show partially attenuated
autolytic activity [133]. Taken together, these observations suggest
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embedded within its own structure, and these factors are regulated
by alternative splicing.
4.3. Hunt for the moment of activation
A compelling question is, even after the active structure of CAPN2/
S1[m-calpain] was revealed, how such functional entity is derived in
vivo. One of the classical unsolved frustrations in the ﬁeld of calpain is
that in vitro activation of calpain requires at least μM order of Ca2+,
which is almost unavailable in vivo. To explain this, the vicinity of
plasmamembrane is proposed as a favorable spot for the activation of
calpain, and in vitro experiment has shown that phospholipids, a
major component of plasma membrane, lowered Ca2+-concentration
required for activating calpain [134–136]. It is also proposed that a
limited portion of calpain whose localization coincides with the spot
where Ca2+-concentration substantially increases is sufﬁcient for
fulﬁll its function.
To ultimately solve the question, it is essential to detect the
moment of calpain activation in situ/in vivo. For this, several attempts
have been successful using speciﬁc antibodies for the aa sequence
generated de novo in substrate protein and calpain itself [137,138].
Taking an advantage of the 3-D structural knowledge on calpain
activation, it would be very useful to develop reagents that label
calpain molecules exclusively in active conformation, such as speciﬁc
antibodies, low-molecular compounds, or substrate analogs.
There are several calpain homologs whose activities have yet to be
identiﬁed, although their biological/physiological importance has
already been demonstrated. For example, CAPN10 is related to a risk
factor for non-insulin-dependent (type 2) diabetes [139] and nematode
TRA-3[CLP-5], whose human homolog is CAPN5[hTRA-3], is involved in
sex determination [55,140]. On the other hand, eutherian CAPN6 is a
peculiar case in that it contains natural aa substitutions in the Cys
residue of the active site triad (to Lys in humans) [74], and has been
shown to be related with microtubule dynamics [141,142]. More
intriguingly, CAPN6 in opossum (Monodelphis domestic) and chickens
contains a complete set of active site residues (Cys–His–Asn), and frogs
and ﬁsh have three functional TRA-3 homologs. Such diversemolecular
nature among calpain homologs does not warrant uniform approach
towards their activationmechanism,whichmight indicate thenecessity
to throw off a prejudice that calpain is a protease.
4.4. Trials to elucidate the substrate speciﬁcity of calpain
It is thought that the conventional calpains, CAPN1/S1[μ-calpain]
and CAPN2/S1[m-calpain], have almost indistinguishable substrate
speciﬁcity. The constraints imposed by the cleft size in the CysPc
domain highly conserved among all calpains, they all may prefer to
digest inter-domain unstructured regions like the conventional
calpains do. On the other hand, novel substrates identiﬁed for other
calpains are not necessarily good substrates for conventional calpains.
For example, calpastatin is a good substrate, not an inhibitor, for
CAPN3[p94] [90]. Likewise, β-COP, a subunit of the coatomer complex,
is sensitively proteolyzed by CAPN8[nCL-2] but probably less sensitive
to conventional calpains [124]. Such distinctions suggest the impor-
tance of interfaces between calpain and substrate other than the
active-site cleft. Potentially stretchable sequences linking the domain
structures within the substrate might not ﬁt into the cleft if the
protein does not form a stable complex with calpain [130].
For binding/recognizing substrates, the C2L domain is also impor-
tant. Active CAPN2/S1[m-calpain] co-crystalized with calpastatin
fragment showed that more than 15 aar of calpastatin are in contact
with the C2L domain [27,28]. Comparison of the 3D structures of C2L
domains of CAPN2[mCL] and CAPN7[PalBH] (the distal C2L) revealed
their highly conserved β-sandwich structure (Fig. 4B), regardless of
somewhat low aa identity between them (ca. 21%). There are, however,three loops that are distinct between them: the acidic loop (between
β2/β3) and the basic loop (β3/β4) in CAPN2[mCL] donot exist in CAPN7
[PalBH], whereas the Gly-rich loop (β4/β5) in the latter corresponds to
the α-helix structure in the former that points in a different direction,
contacting with calpastatin (Fig. 4B). These structural differences may
reﬂect distinct substrate recognition between these two calpains.
Several independent approaches have sought to deduce the rules
governing the substrate speciﬁcity of calpain [143–145]. One
advantage of using inductive methodologies is that such knowledge
is useful for the design of speciﬁc calpain substrates or probes that can
be used to detect active calpains. In parallel with these studies, the
aim is to construct a prediction tool by processing the experimental
result for machine learning [146]. A draft version can be found at
http://calpain.org/ [147]. Such systematic characterization of calpain-
mediated proteolysis enables the use of thought-experiments. This
approach has also been used to identify the particular characteristics
of the caspase system [148–150]. Combining this approach with
“ordinary” experiments should prove effective in identifying novel
calpain functions.
5. Conclusions and perspectives
This review summarizes both classical and state of the art research
in the ﬁeld of calpain biology. The important ﬁndings from
biochemical studies now need to be veriﬁed in vivo. For this purpose,
recent technical advances should be incorporated and optimized to
reﬂect the diverse and complex nature of the calpain family. There are
still somany exciting aspects of this enigmatic family of proteases that
await discovery. The fact that many difﬁcult questions still exist
within the ﬁeld of calpain research should ignite a passion to ﬁnd the
answers. This is the way that calpain research has been, and always
will be, carried out.
Acknowledgments
We again sincerely dedicate this paper to thememory of Prof. Koichi
Suzuki. We thank Prof. Vito Turk for giving us the opportunity to write
this review. We appreciate the invaluable support from all the
laboratory members. This work was supported in part by MEXT.
KAKENHI 18076007 (H.S.), 22770139 (Y.O.), JSPS.KAKENHI 20370055
(H.S.), and a Takeda Science Foundation research grant (H.S.).
References
[1] D.E. Croall, G.N. DeMartino, Calcium-activated neutral protease (calpain)
system: structure, function, and regulation, Physiol. Rev. 71 (1991) 813–847.
[2] D.E. Goll, V.F. Thompson, H. Li, W. Wei, J. Cong, The calpain system, Physiol. Rev.
83 (2003) 731–801.
[3] K. Suzuki, S. Hata, Y. Kawabata, H. Sorimachi, Structure, activation, and biology of
calpain, Diabetes 53 (2004) S12–S18.
[4] H. Sorimachi, S. Hata, Y. Ono, Calpain chronicle — an enzyme family under
multidisciplinary characterization, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 87
(2011) 287–327.
[5] H. Sorimachi, S. Hata, Y. Ono, Impact of genetic insights into calpain biology, J.
Biochem. 150 (2011) 23–37.
[6] G. Guroff, A neutral calcium-activated proteinase from the soluble fraction of rat
brain, J. Biol. Chem. 239 (1964) 149–155.
[7] R.B. Huston, E.G. Krebs, Activation of skeletal muscle phosphorylase kinase by
Ca2+. II. Identiﬁcation of the kinase activating factor as a proteolytic enzyme,
Biochemistry 7 (1968) 2116–2122.
[8] W.A. Busch, M.H. Stromer, D.E. Goll, A. Suzuki, Ca2+-speciﬁc removal of Z lines
from rabbit skeletal muscle, J. Cell Biol. 52 (1972) 367–381.
[9] W.L. Meyer, E.H. Fischer, E.G. Krebs, Activation of skeletal muscle phosphorylase
kinase by Ca2+, Biochemistry 3 (1964) 1033–1039.
[10] S. Ishiura, H. Murofushi, K. Suzuki, K. Imahori, Studies of a calcium-activated
neutral protease from chicken skeletal muscle. I. Puriﬁcation and characteriza-
tion, J. Biochem. 84 (1978) 225–230.
[11] A. Marchler-Bauer, J.B. Anderson, F. Chitsaz, M.K. Derbyshire, C. DeWeese-Scott,
J.H. Fong, L.Y. Geer, R.C. Geer, N.R. Gonzales, M. Gwadz, S. He, D.I. Hurwitz, J.D.
Jackson, Z. Ke, C.J. Lanczycki, C.A. Liebert, C. Liu, F. Lu, S. Lu, G.H. Marchler, M.
Mullokandov, J.S. Song, A. Tasneem, N. Thanki, R.A. Yamashita, D. Zhang, N.
Zhang, S.H. Bryant, CDD: speciﬁc functional annotation with the Conserved
Domain Database, Nucleic Acids Res. 37 (2009) D205–D210.
234 Y. Ono, H. Sorimachi / Biochimica et Biophysica Acta 1824 (2012) 224–236[12] N.O. Carragher, Calpain inhibition: a therapeutic strategy targeting multiple
disease states, Curr. Pharm. Des. 12 (2006) 615–638.
[13] S. Biswas, F. Harris, S. Dennison, J. Singh, D.A. Phoenix, Calpains: targets of
cataract prevention? Trends Mol. Med. 10 (2004) 78–84.
[14] D. Branca, Calpain-related diseases, Biochem. Biophys. Res. Commun. 322 (2004)
1098–1104.
[15] T. Yamashima, Ca2+-dependent proteases in ischemic neuronal death: a
conserved ‘calpain–cathepsin cascade’ from nematodes to primates, Cell Calcium
36 (2004) 285–293.
[16] M.A. Badalamente, A. Stracher, Delay of muscle degeneration and necrosis inmdx
mice by calpain inhibition, Muscle Nerve 23 (2000) 106–111.
[17] R.T. Bartus, N.J. Hayward, P.J. Elliott, S.D. Sawyer, K.L. Baker, R.L. Dean, A.
Akiyama, J.A. Straub, S.L. Harbeson, Z. Li, et al., Calpain inhibitor AK295 protects
neurons from focal brain ischemia. Effects of postocclusion intra-arterial
administration, Stroke 25 (1994) 2265–2270.
[18] H. Sugita, S. Ishiura, K. Suzuki, K. Imahori, Ca-activated neutral protease and its
inhibitors: in vitro effect on intact myoﬁbrils, Muscle Nerve 3 (1980) 335–339.
[19] H. Sorimachi, S. Hata, Y. Ono, Expanding members and roles of the calpain
superfamily and their genetically modiﬁed animals, Exp. Anim. 59 (2010)
549–566.
[20] K. Tanaka, The proteasome: overview of structure and functions, Proc. Jpn. Acad.
Ser. B Phys. Biol. Sci. 85 (2009) 12–36.
[21] N. Mizushima, B. Levine, Autophagy in mammalian development and differen-
tiation, Nat. Cell Biol. 12 (2010) 823–830.
[22] S.W. Tait, D.R. Green, Mitochondria and cell death: outer membrane permea-
bilization and beyond, Nat. Rev. Mol. Cell. Biol. 11 (2010) 621–632.
[23] C.M. Hosﬁeld, J.S. Elce, P.L. Davies, Z. Jia, Crystal structure of calpain reveals the
structural basis for Ca2+-dependent protease activity and a novel mode of
enzyme activation, EMBO J. 18 (1999) 6880–6889.
[24] S. Strobl, C. Fernandez-Catalan, M. Braun, R. Huber, H. Masumoto, K. Nakagawa, A.
Irie, H. Sorimachi, G. Bourenkow, H. Bartunik, K. Suzuki, W. Bode, The crystal
structure of calcium-free human m-calpain suggests an electrostatic switch
mechanism foractivationby calcium, Proc.Natl. Acad. Sci.U.S.A. 97 (2000) 588–592.
[25] T. Moldoveanu, C.M. Hosﬁeld, D. Lim, J.S. Elce, Z. Jia, P.L. Davies, A Ca2+ switch
aligns the active site of calpain, Cell 108 (2002) 649–660.
[26] T. Moldoveanu, C.M. Hosﬁeld, D. Lim, Z. Jia, P.L. Davies, Calpain silencing by a
reversible intrinsic mechanism, Nat. Struct. Biol. 10 (2003) 371–378.
[27] T. Moldoveanu, K. Gehring, D.R. Green, Concerted multi-pronged attack by
calpastatin to occlude the catalytic cleft of heterodimeric calpains, Nature 456
(2008) 404–408.
[28] R.A. Hanna, R.L. Campbell, P.L. Davies, Calcium-bound structure of calpain and its
mechanism of inhibition by calpastatin, Nature 456 (2008) 409–412.
[29] K. Suzuki, H. Sorimachi, T. Yoshizawa, K. Kinbara, S. Ishiura, Calpain: novel family
members, activation, and physiologic function, Biol. Chem. Hoppe Seyler 376
(1995) 523–529.
[30] S. Ohno, Y. Emori, S. Imajoh, H. Kawasaki, M. Kisaragi, K. Suzuki, Evolutionary
origin of a calcium-dependent protease by fusion of genes for a thiol protease
and a calcium-binding protein? Nature 312 (1984) 566–570.
[31] M. Maki, S.V. Narayana, K. Hitomi, A growing family of the Ca2+-binding proteins
with ﬁve EF-hand motifs, Biochem. J. 328 (1997) 718–720.
[32] Y. Ono, H. Sorimachi, K. Suzuki, Structure and physiology of calpain, an enigmatic
protease, Biochem. Biophys. Res. Commun. 245 (1998) 289–294.
[33] H. Sorimachi, S. Ishiura, K. Suzuki, A novel tissue-speciﬁc calpain species
expressed predominantly in the stomach comprises two alternative splicing
products with and without Ca2+-binding domain, J. Biol. Chem. 268 (1993)
19476–19482.
[34] C. Yorikawa, E. Takaya, Y. Osako, R. Tanaka, Y. Terasawa, T. Hamakubo, Y.
Mochizuki, H. Iwanari, T. Kodama, T. Maeda, K. Hitomi, H. Shibata, M. Maki,
Human calpain 7/PalBH associates with a subset of ESCRT-III-related proteins in
its N-terminal region and partly localizes to endocytic membrane compart-
ments, J. Biochem. 143 (2008) 731–745.
[35] Y. Osako, Y. Maemoto, R. Tanaka, H. Suzuki, H. Shibata, M. Maki, Autolytic activity
of human calpain 7 is enhanced by ESCRT-III-related protein IST1 through MIT-
MIM interaction, FEBS J. 277 (2010) 4412–4426.
[36] K. Ojima, Y. Ono, C. Ottenheijm, S. Hata, H. Suzuki, H. Granzier, H. Sorimachi,
Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal
muscles, J. Mol. Biol. 407 (2011) 439–449.
[37] D.J. Macqueen, M.L. Delbridge, S. Manthri, I.A. Johnston, A newly classiﬁed
vertebrate calpain protease, directly ancestral to CAPN1 and 2, episodically
evolved a restricted physiological function in placental mammals, Mol. Biol. Evol.
27 (2010) 1886–1902.
[38] D.J. Macqueen, L. Meischke, S. Manthri, A. Anwar, C. Solberg, I.A. Johnston,
Characterisation of capn1, capn2-like, capn3 and capn11 genes in Atlantic halibut
(Hippoglossus hippoglossus L.): transcriptional regulation across tissues and in
skeletal muscle at distinct nutritional states, Gene 453 (2010) 45–58.
[39] K. Andresen, T.D. Tom, M. Strand, Characterization of cDNA clones encoding a
novel calcium-activated neutral proteinase from Schistosoma mansoni, J. Biol.
Chem. 266 (1991) 15085–15090.
[40] P. Friedrich, P. Tompa, A. Farkas, The calpain-system of Drosophila melanogaster:
coming of age, Bioessays 26 (2004) 1088–1096.
[41] P. Syntichaki, K. Xu, M. Driscoll, N. Tavernarakis, Speciﬁc aspartyl and calpain
proteases are required for neurodegeneration in C. elegans, Nature 419 (2002)
939–944.
[42] K. Ersfeld, H. Barraclough, K. Gull, Evolutionary relationships and protein domain
architecture in an expanded calpain superfamily in kinetoplastid parasites, J.
Mol. Evol. 61 (2005) 742–757.[43] S.E. Lid, D. Gruis, R. Jung, J.A. Lorentzen, E. Ananiev, M. Chamberlin, X. Niu, R.
Meeley, S. Nichols, O.A. Olsen, The defective kernel 1 (dek1) gene required for
aleurone cell development in the endosperm of maize grains encodes a
membrane protein of the calpain gene superfamily, Proc. Natl. Acad. Sci. U.S.A.
99 (2002) 5460–5465.
[44] G.C. Correa, M. Margis-Pinheiro, R. Margis, Identiﬁcation, classiﬁcation and
expression pattern analysis of sugarcane cysteine proteinases, Genet. Mol. Biol.
24 (2001) 275–283.
[45] E. Futai, H. Sorimachi, S.Y. Jeong, K. Kitamoto, S. Ishiura, K. Suzuki, Aspergillus
oryzae palBory encodes a calpain-like protease: homology to Emericella nidulans
PalB and conservation of functional regions, J. Biosci. Bioeng. 88 (1999) 438–440.
[46] T.N. Dear, A. Moller, T. Boehm, CAPN11: a calpain with highmRNA levels in testis
and located on chromosome 6, Genomics 59 (1999) 243–247.
[47] S. Hata, M. Abe, H. Suzuki, F. Kitamura, N. Toyama-Sorimachi, K. Abe, K. Sakimura,
H. Sorimachi, Calpain 8/nCL-2 and calpain 9/nCL-4 constitute an active protease
complex, G-calpain, involved in gastric mucosal defense, PLoS Genet. 6 (2010)
e1001040.
[48] Y. Cao, H. Zhao, H. Grunz, xCL-2 is a novel m-type calpain and disrupts
morphogenetic movements during embryogenesis in Xenopus laevis, Dev.
Growth Differ. 43 (2001) 563–571.
[49] E. Futai, T. Kubo, H. Sorimachi, K. Suzuki, T. Maeda, Molecular cloning of PalBH, a
mammalian homologue of the Aspergillus atypical calpain PalB, Biochim.
Biophys. Acta 1517 (2001) 316–319.
[50] M.X. Caddick, A.G. Brownlee, H.N. Arst Jr., Regulation of gene expression by pH of
the growthmedium inAspergillus nidulans,Mol. Gen. Genet. 203 (1986) 346–353.
[51] S.H. Denison, M. Orejas, H.N. Arst Jr., Signaling of ambient pH in Aspergillus
involves a cysteine protease, J. Biol. Chem. 270 (1995) 28519–28522.
[52] S. Negrete-Urtasun, W. Reiter, E. Diez, S.H. Denison, J. Tilburn, E.A. Espeso, M.A.
Penalva, H.N. Arst Jr., Ambient pH signal transduction in Aspergillus: completion
of gene characterization, Mol. Microbiol. 33 (1999) 994–1003.
[53] E. Futai, T. Maeda, H. Sorimachi, K. Kitamoto, S. Ishiura, K. Suzuki, The protease
activity of a calpain-like cysteine protease in Saccharomyces cerevisiae is required
for alkaline adaptation and sporulation, Mol. Gen. Genet. 260 (1999) 559–568.
[54] M. Hayashi, T. Fukuzawa, H. Sorimachi, T. Maeda, Constitutive activation of the
pH-responsive Rim101 pathway in yeast mutants defective in late steps of the
MVB/ESCRT pathway, Mol. Cell. Biol. 25 (2005) 9478–9490.
[55] T.M. Barnes, J. Hodgkin, The tra-3 sex determination gene of Caenorhabditis
elegans encodes a member of the calpain regulatory protease family, EMBO J. 15
(1996) 4477–4484.
[56] N. Mugita, Y. Kimura, M. Ogawa, H. Saya, M. Nakao, Identiﬁcation of a novel,
tissue-speciﬁc calpain htra-3; a human homologue of the Caenorhabditis elegans
sex determination gene, Biochem. Biophys. Res. Commun. 239 (1997) 845–850.
[57] S.J. Delaney, D.C. Hayward, F. Barleben, K.F. Fischbach, G.L. Miklos, Molecular
cloning and analysis of small optic lobes, a structural brain gene of Drosophila
melanogaster, Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7214–7218.
[58] M. Kamei, G.C. Webb, I.G. Young, H.D. Campbell, SOLH, a human homologue of
the Drosophila melanogaster small optic lobes gene is a member of the calpain and
zinc-ﬁnger gene families and maps to human chromosome 16p13.3 near CATM
(cataract with microphthalmia), Genomics 51 (1998) 197–206.
[59] M. Kamei, G.C. Webb, K. Heydon, I.A. Hendry, I.G. Young, H.D. Campbell, Solh, the
mouse homologue of the Drosophila melanogaster small optic lobes gene:
organization, chromosomal mapping, and localization of gene product to the
olfactory bulb, Genomics 64 (2000) 82–89.
[60] C.Wang, J.K. Barry, Z. Min, G. Tordsen, A.G. Rao, O.A. Olsen, The calpain domain of
the maize DEK1 protein contains the conserved catalytic triad and functions as a
cysteine proteinase, J. Biol. Chem. 278 (2003) 34467–34474.
[61] R. Margis, M. Margis-Pinheiro, Phytocalpains: orthologous calcium-dependent
cysteine proteinases, Trends Plant Sci. 8 (2003) 58–62.
[62] J.W. Ahn, M. Kim, J.H. Lim, G.T. Kim, H.S. Pai, Phytocalpain controls the
proliferation and differentiation fates of cells in plant organ development, Plant J.
38 (2004) 969–981.
[63] K. Hibara, M. Obara, E. Hayashida, M. Abe, T. Ishimaru, H. Satoh, J. Itoh, Y. Nagato,
The ADAXIALIZED LEAF1 gene functions in leaf and embryonic pattern formation
in rice, Dev. Biol. 334 (2009) 345–354.
[64] K.L. Johnson, K.A. Degnan, J.R. Walker, G.C. Ingram, AtDEK1 is essential for
speciﬁcation of embryonic epidermal cell fate, Plant J. 44 (2005) 114–127.
[65] S.E. Lid, L. Olsen, R. Nestestog, M. Aukerman, R.C. Brown, B. Lemmon, M. Mucha,
H.G. Opsahl-Sorteberg, O.A. Olsen, Mutation in the Arabidopisis thaliana DEK1
calpain gene perturbs endosperm and embryo development while over-
expression affects organ development globally, Planta 221 (2005) 339–351.
[66] K.L. Johnson, C. Faulkner, C.E. Jeffree, G.C. Ingram, The phytocalpain defective
kernel 1 is a novel Arabidopsis growth regulator whose activity is regulated by
proteolytic processing, Plant Cell 20 (2008) 2619–2630.
[67] Q. Tian, L. Olsen, B. Sun, S.E. Lid, R.C. Brown, B.E. Lemmon, K. Fosnes, D.F. Gruis, H.
G. Opsahl-Sorteberg, M.S. Otegui, O.A. Olsen, Subcellular localization and
functional domain studies of DEFECTIVE KERNEL1 in maize and Arabidopsis
suggest a model for aleurone cell fate speciﬁcation involving CRINKLY4 and
SUPERNUMERARY ALEURONE LAYER1, Plant Cell 19 (2007) 3127–3145.
[68] P. Dutt, D.E. Croall, S.C. Arthur, T. De Veyra, K. Williams, J.S. Elce, P.A. Greer, m-
Calpain is required for preimplantation embryonic development in mice, BMC
Dev. Biol. 6 (2006) 3.
[69] I. Richard, O. Broux, V. Allamand, F. Fougerousse, N. Chiannilkulchai, N. Bourg, L.
Brenguier, C. Devaud, P. Pasturaud, C. Roudaut, D. Hillaire, M.-R. Passos-Bueno,
M. Zats, J.A. Tischﬁeld, M. Fardeau, C.E. Jackson, D. Cohen, J.S. Beckmann,
Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular
dystrophy type 2A, Cell 81 (1995) 27–40.
235Y. Ono, H. Sorimachi / Biochimica et Biophysica Acta 1824 (2012) 224–236[70] M. Yamada, Y. Yoshida, D. Mori, T. Takitoh, M. Kengaku, H. Umeshima, K. Takao,
T. Miyakawa, M. Sato, H. Sorimachi, A. Wynshaw-Boris, S. Hirotsune, Inhibition
of calpain increases LIS1 expression and partially rescues in vivo phenotypes in a
mouse model of lissencephaly, Nat. Med. 15 (2009) 1202–1207.
[71] M. Yamada, S. Hirotsune, A. Wynshaw-Boris, A novel strategy for therapeutic
intervention for the genetic disease: preventing proteolytic cleavage using small
chemical compound, Int. J. Biochem. Cell Biol. 42 (2010) 1401–1407.
[72] H. Sorimachi, S. Imajoh-Ohmi, Y. Emori, H. Kawasaki, S. Ohno, Y. Minami, K.
Suzuki, Molecular cloning of a novel mammalian calcium-dependent protease
distinct from both m- and mu-types. Speciﬁc expression of the mRNA in skeletal
muscle, J. Biol. Chem. 264 (1989) 20106–20111.
[73] T.N. Dear, T. Boehm, Diverse mRNA expression patterns of the mouse calpain
genes Capn5, Capn6 and Capn11 during development, Mech. Dev. 89 (1999)
201–209.
[74] N. Dear, K. Matena, M. Vingron, T. Boehm, A new subfamily of vertebrate calpains
lacking a calmodulin-like domain: implications for calpain regulation and
evolution, Genomics 45 (1997) 175–184.
[75] T.N. Dear, N.T. Meier, M. Hunn, T. Boehm, Gene structure, chromosomal
localization, and expression pattern of Capn12, a new member of the calpain
large subunit gene family, Genomics 68 (2000) 152–160.
[76] H. Sorimachi, N.E. Forsberg, H.J. Lee, S.Y. Joeng, I. Richard, J.S. Beckmann, S.
Ishiura, K. Suzuki, Highly conserved structure in the promoter region of the gene
for muscle-speciﬁc calpain, p94, Biol. Chem. 377 (1996) 859–864.
[77] Y. Kawabata, S. Hata, Y. Ono, Y. Ito, K. Suzuki, K. Abe, H. Sorimachi, Newly
identiﬁed exons encoding novel variants of p94/calpain 3 are expressed
ubiquitously and overlap the α-glucosidase C gene, FEBS Lett. 555 (2003)
623–630.
[78] S. Hata, K. Nishi, T. Kawamoto, H.J. Lee, H. Kawahara, T. Maeda, Y. Shintani, H.
Sorimachi, K. Suzuki, Both the conserved and the unique gene structure of
stomach-speciﬁc calpains reveal processes of calpain gene evolution, J. Mol. Evol.
53 (2001) 191–203.
[79] S. Imajoh, H. Kawasaki, K. Suzuki, The COOH-terminal E-F hand structure of
calcium-activated neutral protease (CANP) is important for the association of
subunits and resulting proteolytic activity, J. Biochem. 101 (1987) 447–452.
[80] G.D. Lin, D. Chattopadhyay, M. Maki, K.K. Wang, M. Carson, L. Jin, P.W. Yuen, E.
Takano, M. Hatanaka, L.J. DeLucas, S.V. Narayana, Crystal structure of calcium
bound domain VI of calpain at 1.9 Å resolution and its role in enzyme assembly,
regulation, and inhibitor binding, Nat. Struct. Biol. 4 (1997) 539–547.
[81] H. Blanchard, P. Grochulski, Y. Li, J.S. Arthur, P.L. Davies, J.S. Elce, M. Cygler,
Structure of a calpain Ca2+-binding domain reveals a novel EF-hand and Ca2+-
induced conformational changes, Nat. Struct. Biol. 4 (1997) 532–538.
[82] T. Yoshizawa, H. Sorimachi, S. Tomioka, S. Ishiura, K. Suzuki, A catalytic subunit of
calpain possesses full proteolytic activity, FEBS Lett. 358 (1995) 101–103.
[83] J.S. Arthur, J.S. Elce, C. Hegadorn, K.Williams, P.A. Greer, Disruption of themurine
calpain small subunit gene, Capn4: calpain is essential for embryonic
development but not for cell growth and division, Mol. Cell. Biol. 20 (2000)
4474–4481.
[84] U.J. Zimmerman, L. Boring, J.H. Pak, N. Mukerjee, K.K. Wang, The calpain small
subunit gene is essential: its inactivation results in embryonic lethality, IUBMB
Life 50 (2000) 63–68.
[85] M. Maki, Y. Kitaura, H. Satoh, S. Ohkouchi, H. Shibata, Structures, functions and
molecular evolution of the penta-EF-hand Ca2+-binding proteins, Biochim.
Biophys. Acta 1600 (2002) 51–60.
[86] E. Schad, A. Farkas, G. Jekely, P. Tompa, P. Friedrich, A novel human small subunit
of calpains, Biochem. J. 362 (2002) 383–388.
[87] R. Kiss, D. Kovacs, P. Tompa, A. Perczel, Local structural preferences of calpastatin,
the intrinsically unstructured protein inhibitor of calpain, Biochemistry 47
(2008) 6936–6945.
[88] S. Hata, N. Doi, F. Kitamura, H. Sorimachi, Stomach-speciﬁc calpain, nCL-2/
calpain 8, is active without calpain regulatory subunit and oligomerizes through
C2-like domains, J. Biol. Chem. 282 (2007) 27847–27856.
[89] H.J. Lee, S. Tomioka, K. Kinbara, H. Masumoto, S.Y. Jeong, H. Sorimachi, S. Ishiura,
K. Suzuki, Characterization of a human digestive tract-speciﬁc calpain, nCL-4,
expressed in the baculovirus system, Arch. Biochem. Biophys. 362 (1999) 22–31.
[90] Y. Ono, K. Kakinuma, F. Torii, A. Irie, K. Nakagawa, S. Labeit, K. Abe, K. Suzuki, H.
Sorimachi, Possible regulation of the conventional calpain system by skeletal
muscle-speciﬁc calpain, p94/calpain 3, J. Biol. Chem. 279 (2004) 2761–2771.
[91] Y. Emori, H. Kawasaki, S. Imajoh, K. Imahori, K. Suzuki, Endogenous inhibitor for
calcium-dependent cysteine protease contains four internal repeats that could
be responsible for its multiple reactive sites, Proc. Natl. Acad. Sci. U.S.A. 84
(1987) 3590–3594.
[92] M. Maki, E. Takano, H. Mori, R. Kannagi, T. Murachi, M. Hatanaka, Repetitive
region of calpastatin is a functional unit of the proteinase inhibitor, Biochem.
Biophys. Res. Commun. 143 (1987) 300–308.
[93] M. Maki, E. Takano, H. Mori, A. Sato, T. Murachi, M. Hatanaka, All four internally
repetitive domains of pig calpastatin possess inhibitory activities against
calpains I and II, FEBS Lett. 223 (1987) 174–180.
[94] S. Pontremoli, E. Melloni, The role of calpain and protein kinase C in activation of
human neutrophils, Prog. Clin. Biol. Res. 282 (1988) 195–208.
[95] M. Noguchi, A. Sarin, M.J. Aman, H. Nakajima, E.W. Shores, P.A. Henkart, W.J.
Leonard, Functional cleavage of the common cytokine receptor γ chain (γc) by
calpain, Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 11534–11539.
[96] T. Nakagawa, J. Yuan, Cross-talk between two cysteine protease families.
Activation of caspase-12 by calpain in apoptosis, J. Cell Biol. 150 (2000) 887–894.
[97] N.N. Danial, S.J. Korsmeyer, Cell death: critical control points, Cell 116 (2004)
205–219.[98] A. Wells, A. Huttenlocher, D.A. Lauffenburger, Calpain proteases in cell adhesion
and motility, Int. Rev. Cytol. 245 (2005) 1–16.
[99] R.L. Mellgren, W. Zhang, K. Miyake, P.L. McNeil, Calpain is required for the rapid,
calcium-dependent repair of wounded plasma membrane, J. Biol. Chem. 282
(2007) 2567–2575.
[100] L. Leloup, H. Shao, Y.H. Bae, B. Deasy, D. Stolz, P. Roy, A. Wells, m-Calpain
activation is regulated by its membrane localization and by its binding to
phosphatidylinositol 4,5-bisphosphate, J. Biol. Chem. 285 (2010) 33549–33566.
[101] E. Diez, J. Alvaro, E.A. Espeso, L. Rainbow, T. Suarez, J. Tilburn, H.N. Arst Jr., M.A.
Penalva, Activation of the Aspergillus PacC zinc ﬁnger transcription factor
requires two proteolytic steps, EMBO J. 21 (2002) 1350–1359.
[102] A. Hervas-Aguilar, J.M. Rodriguez, J. Tilburn, H.N. Arst Jr., M.A. Penalva, Evidence
for the direct involvement of the proteasome in the proteolytic processing of the
Aspergillus nidulans zinc ﬁnger transcription factor PacC, J. Biol. Chem. 282
(2007) 34735–34747.
[103] S.S. Su, A.P. Mitchell, Molecular characterization of the yeast meiotic regulatory
gene RIM1, Nucleic Acids Res. 21 (1993) 3789–3797.
[104] W. Li, A.P. Mitchell, Proteolytic activation of Rim1p, a positive regulator of yeast
sporulation and invasive growth, Genetics 145 (1997) 63–73.
[105] S. Blanchin-Roland, G. Da Costa, C. Gaillardin, ESCRT-I components of the
endocytic machinery are required for Rim101-dependent ambient pH regulation
in the yeast Yarrowia lipolytica, Microbiology 151 (2005) 3627–3637.
[106] O. Rodriguez-Galan, A. Galindo, A. Hervas-Aguilar, H.N. Arst Jr., M.A. Penalva,
Physiological involvement in pH signaling of Vps24-mediated recruitment of
Aspergillus PalB cysteine protease to ESCRT-III, J. Biol. Chem. 284 (2009)
4404–4412.
[107] A.L. Kullas, M. Li, D.A. Davis, Snf7p, a component of the ESCRT-III protein
complex, is an upstream member of the RIM101 pathway in Candida albicans,
Eukaryot. Cell 3 (2004) 1609–1618.
[108] W. Xu, F.J. Smith Jr., R. Subaran, A.P. Mitchell, Multivesicular body-ESCRT
components function in pH response regulation in Saccharomyces cerevisiae and
Candida albicans, Mol. Biol. Cell 15 (2004) 5528–5537.
[109] M. Missotten, A. Nichols, K. Rieger, R. Sadoul, Alix, a novel mouse protein
undergoing calcium-dependent interaction with the apoptosis-linked-gene 2
(ALG-2) protein, Cell Death Differ. 6 (1999) 124–129.
[110] P. Vito, L. Pellegrini, C. Guiet, L. D'Adamio, Cloning of AIP1, a novel protein that
associates with the apoptosis-linked gene ALG-2 in a Ca2+-dependent reaction, J.
Biol. Chem. 274 (1999) 1533–1540.
[111] K. Katoh, H. Shibata, H. Suzuki, A. Nara, K. Ishidoh, E. Kominami, T. Yoshimori, M.
Maki, The ALG-2-interacting protein Alix associates with CHMP4b, a human
homologue of yeast Snf7 that is involved in multivesicular body sorting, J. Biol.
Chem. 278 (2003) 39104–39113.
[112] R. Sadoul, Do Alix and ALG-2 really control endosomes for better or for worse?
Biol. Cell 98 (2006) 69–77.
[113] I. Richard, C. Roudaut, S. Marchand, S. Baghdiguian, M. Herasse, D. Stockholm, Y.
Ono, L. Suel, N. Bourg, H. Sorimachi, G. Lefranc, M. Fardeau, A. Sebille, J.S.
Beckmann, Loss of calpain 3 proteolytic activity leads to muscular dystrophy and
to apoptosis-associated IκBα/nuclear factor κB pathway perturbation in mice, J.
Cell Biol. 151 (2000) 1583–1590.
[114] I. Kramerova, E. Kudryashova, J.G. Tidball, M.J. Spencer, Null mutation of calpain
3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro, Hum.
Mol. Genet. 13 (2004) 1373–1388.
[115] K. Ojima, Y. Kawabata, H. Nakao, K. Nakao, N. Doi, F. Kitamura, Y. Ono, S. Hata, H.
Suzuki, H. Kawahara, J. Bogomolovas, C. Witt, C. Ottenheijm, S. Labeit, H.
Granzier, N. Toyama-Sorimachi, M. Sorimachi, K. Suzuki, T. Maeda, K. Abe, A.
Aiba, H. Sorimachi, Dynamic distribution of muscle-speciﬁc calpain in mice has a
key role in physical-stress adaptation and is impaired in muscular dystrophy, J.
Clin. Invest. 120 (2010) 2672–2683.
[116] V. Solomon, S.H. Lecker, A.L. Goldberg, The N-end rule pathway catalyzes amajor
fraction of the protein degradation in skeletal muscle, J. Biol. Chem. 273 (1998)
25216–25222.
[117] J. Huang, N.E. Forsberg, Role of calpain in skeletal-muscle protein degradation,
Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 12100–12105.
[118] H. Sorimachi, N. Toyama-Sorimachi, T.C. Saido, H. Kawasaki, H. Sugita, M.
Miyasaka, K. Arahata, S. Ishiura, K. Suzuki, Muscle-speciﬁc calpain, p94, is
degraded by autolysis immediately after translation, resulting in disappearance
from muscle, J. Biol. Chem. 268 (1993) 10593–10605.
[119] Y. Ono, K. Ojima, F. Torii, E. Takaya, N. Doi, K. Nakagawa, S. Hata, K. Abe, H.
Sorimachi, Skeletal muscle-speciﬁc calpain is an intracellular Na+-dependent
protease, J. Biol. Chem. 285 (2010) 22986–22998.
[120] C. Hayashi, Y. Ono, N. Doi, F. Kitamura, M. Tagami, R. Mineki, T. Arai, H. Taguchi, M.
Yanagida, S. Hirner, D. Labeit, S. Labeit, H. Sorimachi, Multiple molecular
interactions implicate the connectin/titin N2A region as a modulating scaffold for
p94/calpain 3 activity in skeletal muscle, J. Biol. Chem. 283 (2008) 14801–14814.
[121] H. Sorimachi, K. Kinbara, S. Kimura, M. Takahashi, S. Ishiura, N. Sasagawa, N.
Sorimachi, H. Shimada, K. Tagawa, K. Maruyama, K. Suzuki, Muscle-speciﬁc
calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates
with connectin through IS2, a p94-speciﬁc sequence, J. Biol. Chem. 270 (1995)
31158–31162.
[122] J.S. Beckmann, M. Spencer, Calpain 3, the “gatekeeper” of proper sarcomere
assembly, turnover and maintenance, Neuromuscul. Disord. 18 (2008) 913–921.
[123] K. Ojima, Y. Ono, N. Doi, K. Yoshioka, Y. Kawabata, S. Labeit, H. Sorimachi,
Myogenic stage, sarcomere length, and protease activitymodulate localization of
muscle-speciﬁc calpain, J. Biol. Chem. 282 (2007) 14493–14504.
[124] S. Hata, S. Koyama, H. Kawahara, N. Doi, T. Maeda, N. Toyama-Sorimachi, K. Abe,
K. Suzuki, H. Sorimachi, Stomach-speciﬁc calpain, nCL-2, localizes in mucus cells
236 Y. Ono, H. Sorimachi / Biochimica et Biophysica Acta 1824 (2012) 224–236and proteolyzes the β-subunit of coatomer complex, β-COP, J. Biol. Chem. 281
(2006) 11214–11224.
[125] S. Hata, H. Sorimachi, K. Nakagawa, T. Maeda, K. Abe, K. Suzuki, Domain II of m-
calpain is a Ca2+-dependent cysteine protease, FEBS Lett. 501 (2001) 111–114.
[126] M.A. Rey, P.L.Davies, Theprotease coreof themuscle-speciﬁc calpain,p94, undergoes
Ca2+-dependent intramolecular autolysis, FEBS Lett. 532 (2002) 401–406.
[127] T.L. Davis, J.R. Walker, P.J. Finerty Jr., F. Mackenzie, E.M. Newman, S. Dhe-
Paganon, The crystal structures of human calpains 1 and 9 imply diverse
mechanisms of action and auto-inhibition, J. Mol. Biol. 366 (2007) 216–229.
[128] T. Moldoveanu, Z. Jia, P.L. Davies, Calpain activation by cooperative Ca2+ binding
at two non-EF-hand sites, J. Biol. Chem. 279 (2004) 6106–6114.
[129] P. Yuan, M.D. Leonetti, A.R. Pico, Y. Hsiung, R. MacKinnon, Structure of the human
BK channel Ca2+-activation apparatus at 3.0 Å resolution, Science 329 (2010)
182–186.
[130] T. Moldoveanu, R.L. Campbell, D. Cuerrier, P.L. Davies, Crystal structures of
calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the
active site, J. Mol. Biol. 343 (2004) 1313–1326.
[131] S. Tsuji, S. Ishiura, M. Takahashi-Nakamura, T. Katamoto, K. Suzuki, K. Imahori,
Studies on a Ca2+-activated neutral proteinase of rabbit skeletal muscle. II.
Characterization of sulfhydryl groups and a role of Ca2+ ions in this enzyme, J.
Biochem. 90 (1981) 1405–1411.
[132] E. Dainese, R. Minafra, A. Sabatucci, P. Vachette, E. Melloni, I. Cozzani,
Conformational changes of calpain from human erythrocytes in the presence
of Ca2+, J. Biol. Chem. 277 (2002) 40296–40301.
[133] M. Herasse, Y. Ono, F. Fougerousse, E. Kimura, D. Stockholm, C. Beley, D.
Montarras, C. Pinset, H. Sorimachi, K. Suzuki, J.S. Beckmann, I. Richard,
Expression and functional characteristics of calpain 3 isoforms generated
through tissue-speciﬁc transcriptional and posttranscriptional events, Mol.
Cell. Biol. 19 (1999) 4047–4055.
[134] T.C. Saido, M. Shibata, T. Takenawa, H. Murofushi, K. Suzuki, Positive regulation
of mu-calpain action by polyphosphoinositides, J. Biol. Chem. 267 (1992)
24585–24590.
[135] P. Tompa, Y. Emori, H. Sorimachi, K. Suzuki, P. Friedrich, Domain III of calpain is a
Ca2+-regulated phospholipid-binding domain, Biochem. Biophys. Res. Commun.
280 (2001) 1333–1339.
[136] H. Shao, J. Chou, C.J. Baty, N.A. Burke, S.C. Watkins, D.B. Stolz, A. Wells, Spatial
localization of m-calpain to the plasma membrane by phosphoinositide bipho-
sphate binding during epidermal growth factor receptor-mediated activation,
Mol. Cell. Biol. 26 (2006) 5481–5496.
[137] T.C. Saido, H. Suzuki, H. Yamazaki, K. Tanoue, K. Suzuki, In situ capture of mu-
calpain activation in platelets, J. Biol. Chem. 268 (1993) 7422–7426.[138] T.C. Saido, M. Yokota, S. Nagao, I. Yamaura, E. Tani, T. Tsuchiya, K. Suzuki, S.
Kawashima, Spatial resolution of fodrin proteolysis in postischemic brain, J. Biol.
Chem. 268 (1993) 25239–25243.
[139] Y. Horikawa, N. Oda, N.J. Cox, X. Li, M. Orho-Melander, M. Hara, Y. Hinokio, T.H.
Lindner, H. Mashima, P.E. Schwarz, L. del Bosque-Plata, Y. Horikawa, Y. Oda, I.
Yoshiuchi, S. Colilla, K.S. Polonsky, S. Wei, P. Concannon, N. Iwasaki, J. Schulze, L.J.
Baier, C. Bogardus, L. Groop, E. Boerwinkle, C.L. Hanis, G.I. Bell, Genetic variation
in the gene encoding calpain-10 is associated with type 2 diabetes mellitus, Nat.
Genet. 26 (2000) 163–175.
[140] S.B. Sokol, P.E. Kuwabara, Proteolysis in Caenorhabditis elegans sex determina-
tion: cleavage of TRA-2A by TRA-3, Genes Dev. 14 (2000) 901–906.
[141] K. Tonami, Y. Kurihara, S. Arima, K. Nishiyama, Y. Uchijima, T. Asano, H.
Sorimachi, H. Kurihara, Calpain 6, a microtubule-stabilizing protein, regulates
Rac1 activity and cell motility through interaction with GEF-H1, J. Cell Sci. 124
(2011) 1214–1223.
[142] K. Tonami, Y. Kurihara, H. Aburatani, Y. Uchijima, T. Asano, H. Kurihara, Calpain 6
is involved in microtubule stabilization and cytoskeletal organization, Mol. Cell.
Biol. 27 (2007) 2548–2561.
[143] P.R. Stabach, C.D. Cianci, S.B. Glantz, Z. Zhang, J.S. Morrow, Site-directed
mutagenesis of alpha II spectrin at codon 1175 modulates its mu-calpain
susceptibility, Biochemistry 36 (1997) 57–65.
[144] P. Tompa, P. Buzder-Lantos, A. Tantos, A. Farkas, A. Szilagyi, Z. Banoczi, F. Hudecz,
P. Friedrich, On the sequential determinants of calpain cleavage, J. Biol. Chem.
279 (2004) 20775–20785.
[145] D. Cuerrier, T. Moldoveanu, P.L. Davies, Determination of peptide substrate
speciﬁcity for mu-calpain by a peptide library-based approach: the importance
of primed side interactions, J. Biol. Chem. 280 (2005) 40632–40641.
[146] D. duVerle, I. Takigawa, Y. Ono, H. Sorimachi, H. Mamitsuka, CaMPDB: a resource
for calpain and modulatory proteolysis, Genome Inform. 22 (2010) 202–213.
[147] D.A. duVerle, Y. Ono, H. Sorimachi, H. Mamitsuka, Calpain cleavage prediction
using multiple kernel learning, PLoS One 6 (2011) e19035.
[148] C. Backes, J. Kuentzer, H.P. Lenhof, N. Comtesse, E. Meese, GraBCas: a
bioinformatics tool for score-based prediction of Caspase- and Granzyme B-
cleavage sites in protein sequences, Nucleic Acids Res. 33 (2005) W208–W213.
[149] Z.R. Yang, Prediction of caspase cleavage sites using Bayesian bio-basis function
neural networks, Bioinformatics 21 (2005) 1831–1837.
[150] J. Song, H. Tan, H. Shen, K. Mahmood, S.E. Boyd, G.I. Webb, T. Akutsu, J.C.
Whisstock, Cascleave: towards more accurate prediction of caspase substrate
cleavage sites, Bioinformatics 26 (2010) 752–760.
[151] L. Holm, C. Sander, Protein structure comparison by alignment of distance
matrices, J. Mol. Biol. 233 (1993) 123–138.
